---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-24-000050"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:06:23.936679+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance

## Summary
- Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).
- Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.
- Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.
- Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).
- Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%.

## SEC filing metadata
- accession: 0001609550-24-000050
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/0001609550-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955024000050/insp-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-24-000050
- JSON: https://secwatch.observer/filing/0001609550-24-000050.json
- Plain text: https://secwatch.observer/filing/0001609550-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.